Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.
复制标题
DOI：
10.1016/j.ccell.2016.03.007
复制
发表时间：
2016-04-11
期刊：
影响因子：
50.3
通讯作者：
Armstrong SA
中科院分区：
文献类型：
--
作者：
Brien GL;Valerio DG;Armstrong SA
表观基因组是转录输出的关键决定因素。表观基因组内的扰动被认为是许多，也许是所有癌症的关键特征，现在很清楚，表观遗传变化在癌症发展中起着重要作用。这些变化的固有可逆性使它们成为治疗操作的有吸引力的靶标，并且许多靶向基于染色质的机制的小分子目前正在临床试验中。从这个角度来看，我们讨论了如何理解癌症表观基因组是提供洞察疾病的发病机制和通知药物开发。我们还强调了进一步释放癌症表观基因组治疗潜力的其他机会。
The epigenome is a key determinant of transcriptional output. Perturbations within the epigenome are thought to be a key feature of many, perhaps all cancers, and it is now clear that epigenetic changes are instrumental in cancer development. The inherent reversibility of these changes makes them attractive targets for therapeutic manipulation and a number of small molecules targeting chromatin-based mechanisms are currently in clinical trials. In this perspective we discuss how understanding the cancer epigenome is providing insights into disease pathogenesis and informing drug development. We also highlight additional opportunities to further unlock the therapeutic potential within the cancer epigenome.